MDX 220

Drug Profile

MDX 220

Alternative Names: HCC49XH22

Latest Information Update: 27 Apr 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Cancer Institute (USA)
  • Developer IDM S.A.; National Cancer Institute (USA)
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Glycoprotein inhibitors; IgG receptor antagonists; Neoplasm antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 27 Apr 2005 Discontinued - Phase-II for Cancer in USA (unspecified route)
  • 07 Apr 2003 No development reported - Phase-II for Cancer in USA (unspecified route)
  • 18 Feb 2000 IDM will acquire worldwide rights to MDX 220 as part of an expanded oncology agreement with Medarex
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top